On Feb. 16, 2020, Medigen Vaccine Biologics (MVB) and the National Institutes of Health (NIH) announced they had entered a collaboration agreement.

MVC obtained NIH’s COVID-19 vaccine and related biological materials to conduct animal studies in Taiwan. MVC evaluated the feasibility of human clinical trials based on the data from animal studies.